Medtronic OsteoCool™ procedure achieves primary endpoint in multicenter cancer study

 

• Announcing the outcomes in the first 100 patients treated with the OsteoCool™ Radiofrequency Ablation System in the OPuS One Clinical Study, Medtronic (NYSE:MDT) says the study reached the primary endpoint.
• Results published in the Journal of Vascular and Interventional Radiology was based on a multicenter study involving 218 patients at 16 centers in the United States, Europe, and Canada, included outcomes out to six months in the first 100 patients.
• With the results indicating the improvement from baseline to three months post-RFA in worst pain score in the past 24 hours in subjects treated for metastatic lesions in only the thoracic and/or lumbar vertebral body(ies), the study achieved the primary endpoint, the company says.
• One in three cancer patients are left with inadequate treatment or undermanaged pain control, and in this instance, OsteoCool™ system can act as an adjunctive treatment, without disrupting other systemic therapies.
• ‘Results showed rapid pain improvement as early as three days and sustained out to six months’, the company notes, adding 'patients in the study also achieved significant improvements in pain interference and quality of life at all visits.’
• https://seekingalpha.com/news/3644387-medtronics-osteocool-procedure-achieves-primary-endpoint-in-multicenter-cancer-study